Deal type
IP & Technology
11 announced IP & Technology deals, most recent first, with the firms that advised on each.
Most recent
SEARCH ALL 11 Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton Pharmaceuticals 19 Oct 2026
DLA Piper advises Georgian Financial Markets Treasuries Association on strategic partnership with Nasdaq 30 Jul 2026
Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZeneca 14 Jul 2026
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology 18 Dec 2025
Herbert Smith Freehills Kewei advises Fosun Pharma on international licence agreements with Pfizer and Sitala 16 Dec 2025
Ropes & Gray Advises SK Biopharmaceuticals in Worldwide License Agreement with Full-Life Technologies for Radiotherapy Targeting Cancer Cells 18 Sept 2024
Ropes & Gray Represents Nona Biosciences in License Agreement with Pfizer (Seagen) 16 Dec 2023
Ropes & Gray Represents Acumen Pharmaceuticals in Halozyme Therapeutics Global Collaboration and License Agreement 8 Nov 2023
Latham Advises The Chainsmokers on Groundbreaking NFT Transaction 14 May 2022
Linklaters advises Etisalat on new UAE blockchain-based platform to help financial institutions combat fraud and invoice duplication 21 May 2021
Sidley Represents Hengrui Medicine in its License Agreement with CrystalGenomics 4 May 2020